secwatch.observer — SEC 8-K summary
======================================

Issuer:     Edwards Lifesciences Corp (EW)
CIK:        0001099800
Form:       8-K
Filed at:   2025-07-24T23:59:59+00:00
Accession:  0001099800-25-000037
Event type: earnings
Sentiment:  positive
Materiality: 0.82
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Edwards Q2 sales up 11.9% to $1.53B; raises full-year guidance
--------------------------------------------------------------

- Q2 GAAP EPS $0.57; adjusted EPS $0.67.
- TAVR sales $1.1B (+8.9%); TMTT $134.5M (+61.9%); Surgical $267M (+7.7%).
- Full-year sales growth guidance raised to 9-10% (from 8-10%); adjusted EPS expected at high end of $2.40-$2.50.
- SAPIEN M3 CE Mark approved in Q2; 10-year PARTNER II data affirm durability.
- Q3 guidance: sales $1.46-$1.54B, adjusted EPS $0.54-$0.60.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1099800/000109980025000037/0001099800-25-000037-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1099800/000109980025000037/ew-20250724.htm
  HTML page:      https://secwatch.observer/filing/0001099800-25-000037

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer